tbuckley/cabot-search huggingface dataset:
Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections
Authors: Moris Topaz, Ehud Chorin, Arie Lorin Schwartz, Aviram Hochstadt, Avraham Shotan, Itamar Ashkenazi, Mark Kazatsker, Narin-Nard Carmel, Guy Topaz, Yoram Oron, Gilad Margolis, Eyal Nof, Roy Beinart, Michael Glikson, Anna Mazo, Anat Milman, Michal Dekel, Shmuel Banai, Raphael Rosso, Sami Viskin
Journal: Journal of the American College of Cardiology (2023)
Potential Alzheimer's disease therapeutic nano-platform: Discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles
Authors: Jaehoon Kim, Hyeji Um, Na Hee Kim, Dokyoung Kim
Journal: Bioactive Materials (2023)

There has been a lot of basic and clinical research on Alzheimer's disease (AD) over the last 100 years, but its mechanisms and treatments have not been fully clarified. Despite some controversies, the amyloid-beta hypothesis is one of the most widely accepted causes of AD. In this study, we disclose a new amyloid-beta plaque disaggregating agent and an AD brain-targeted delivery system using porous silicon nanoparticles (pSiNPs) as a therapeutic nano-platform to overcome AD. We hypothesized that the negatively charged sulfonic acid functional group could disaggregate plaques and construct a chemical library. As a result of the in vitro assay of amyloid plaques and library screening, we confirmed that 6-amino-2-naphthalenesulfonic acid (ANA) showed the highest efficacy for plaque disaggregation as a hit compound. To confirm the targeted delivery of ANA to the AD brain, a nano-platform was created using porous silicon nanoparticles (pSiNPs) with ANA loaded into the pore of pSiNPs and biotin-polyethylene glycol (PEG) surface functionalization. The resulting nano-formulation, named Biotin-CaCl2-ANA-pSiNPs (BCAP), delivered a large amount of ANA to the AD brain and ameliorated memory impairment of the AD mouse model through the disaggregation of amyloid plaques in the brain. This study presents a new bioactive small molecule for amyloid plaque disaggregation and its promising therapeutic nano-platform for AD brain-targeted delivery.
Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
Authors: Sankar D. Navaneethan, Sophia Zoungas, M. Luiza Caramori, Juliana C.N. Chan, Hiddo J.L. Heerspink, Clint Hurst, Adrian Liew, Erin D. Michos, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Jonathan C. Craig, David J. Tunnicliffe, Marcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing, Ian H. de Boer, Kamlesh Khunti
Journal: Annals of Internal Medicine (2023)

The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline from Kidney Disease: Improving Global Outcomes (KDIGO).The KDIGO Work Group updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the Work Group used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and expert judgment to develop consensus practice points. New evidence led to updating of recommendations in the chapters Comprehensive Care in Patients With Diabetes and CKD (Chapter 1) and Glucose-Lowering Therapies in Patients With T2D and CKD (Chapter 4). New evidence did not change recommendations in the chapters Glycemic Monitoring and Targets in Patients With Diabetes and CKD (Chapter 2), Lifestyle Interventions in Patients With Diabetes and CKD (Chapter 3), and Approaches to Management of Patients With Diabetes and CKD (Chapter 5).The updated guideline includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease (CKD). A focus on preserving kidney function and maintaining well-being is recommended using a layered approach to care, starting with a foundation of lifestyle interventions, self-management, and first-line pharmacotherapy (such as sodium-glucose cotransporter-2 inhibitors) demonstrated to improve clinical outcomes. To this are added additional drugs with heart and kidney protection, such as glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists, and interventions to control risk factors for CKD progression and cardiovascular events, such as blood pressure, glycemia, and lipids.
Migraine
Authors: Niushen Zhang, Matthew S. Robbins
Journal: Annals of Internal Medicine (2023)

Migraine affects about 1 billion people worldwide, and up to 15% of adults in the United States have migraine attacks in any given year. Migraine is associated with substantial adverse socioeconomic and personal effects. It is the second leading cause of years lived with disability worldwide for all ages and the leading cause in women aged 15 to 49 years. Diagnostic uncertainty increases the likelihood of unnecessary investigations and suboptimal management. This article advises clinicians about diagnosing migraine, ruling out secondary headache disorders, developing acute and preventive treatment plans, and deciding when to refer the patient to a specialist.
Annals Graphic Medicine - Prescriptions for Healing
Authors: Sujal Manohar
Journal: Annals of Internal Medicine (2023)

Web ExclusivesJanuary 2023Annals Graphic Medicine - Prescriptions for HealingFREESujal Manohar, BS, BASujal Manohar, BS, BABaylor College of Medicine, Houston, Texas (S.M.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/G22-0026 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Sujal Manohar, BS, BAAffiliations: Baylor College of Medicine, Houston, Texas (S.M.)Disclosures: The author has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G22-0026.Author/Illustrator Information: Sujal Manohar, BS, BA, is a second-year medical student at Baylor College of Medicine (e-mail, sujal.[email protected].edu). Her creative work can be viewed at sujalmanohar.com.This article was published at Annals.org on 10 January 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics January 2023Volume 176, Issue 1 ePublished: 10 January 2023 Issue Published: January 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Colinet–Caplan Syndrome: History of an Outbreak of Autoimmune Disease in Scouring Powder Workers
Authors: Steven Ronsmans, Paul D. Blanc
Journal: Annals of Internal Medicine (2023)

The first modern description linking rheumatoid arthritis to occupational dust exposure is generally attributed to the British physician Anthony Caplan. In 1953, Caplan reported on a "peculiar" nodular pattern on chest radiographs of Welsh coal miners with rheumatoid arthritis that differed from the typical coal workers' pneumoconiosis. However, as early as 1950, the Belgian rheumatologist Émile Colinet described a similar case of rheumatoid arthritis and concomitant pulmonary opacities in a 30-year-old woman with silica exposure. Soon after, he published a second case. Although this condition initially was called Colinet-Caplan syndrome in the Francophone biomedical literature, Colinet's name was later dropped from the eponym. Because Colinet never clearly described the specific occupational context of his cases, Caplan syndrome has been misconstrued as uniquely a disease of coal miners.We attempted to reconstruct the working conditions of Colinet's patients and found that they were packing Vim, a silica-based scouring powder, at the Savonneries Lever Frères factory in Brussels, Belgium. Colinet's cases were only the first 2 in a series of reports of rheumatoid arthritis and other autoimmune diseases, mainly among young women, in those who worked in the production of silica-based scouring powder between the 1930s and 1980s across Europe. The largest outbreak involved 32 cases of autoimmune disease among 50 former workers of a Spanish scouring powder manufacturing facility. After silica in scouring powders was replaced with less hazardous materials later in the 20th century, no further cases have been reported.Although scouring powder disease is a historical phenomenon, autoimmune disorders linked to occupational exposure to silica and coal dust have not disappeared but instead are reemerging among those who work with silica-based artificial stone and in other dusty trades.
Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition
Authors: Jochen Kammermeier, Christopher A Lamb, Kelsey D J Jones, Carl A Anderson, Emma L Baple, Chrissy Bolton, Helen Braggins, Tanya I Coulter, Kimberly C Gilmour, Vicki Gregory, Sophie Hambleton, David Hartley, A Barney Hawthorne, Sarah Hearn, Arian Laurence, Miles Parkes, Richard K Russell, R Alexander Speight, Simon Travis, David C Wilson, Holm H Uhlig
Journal: The Lancet. Gastroenterology & hepatology (2023)
Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study
Authors: Ulrikka Nygaard, Ulla Birgitte Hartling, Jens Nielsen, Lasse Skafte Vestergaard, Kia Hee Schultz Dungu, Jeppe Sylvest Angaard Nielsen, Anna Sellmer, Astrid Thaarup Matthesen, Kim Kristensen, Mette Holm
Journal: The Lancet Child & Adolescent Health (2023)
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
Authors: Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E. Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Thomas E. Stinchcombe, Jeffrey D. Bradley, Everett Vokes
Journal: Journal of Clinical Oncology (2023)

Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated.
Advancing Survivors Knowledge (ASK Study) of Skin Cancer Surveillance After Childhood Cancer: A Randomized Controlled Trial in the Childhood Cancer Survivor Study
Authors: Alan C. Geller, Adina Coroiu, Robyn R. Keske, Sebastien Haneuse, Jessica A. Davine, Karen M. Emmons, Casey L. Daniel, Todd M. Gibson, Aaron J. McDonald, Leslie L. Robison, Ann C. Mertens, Elena B. Elkin, Ashfaq Marghoob, Gregory T. Armstrong
Journal: Journal of Clinical Oncology (2023)

To improve skin cancer screening among survivors of childhood cancer treated with radiotherapy where skin cancers make up 58% of all subsequent neoplasms. Less than 30% of survivors currently complete recommended skin cancer screening.
Microbiome influencers of checkpoint blockade–associated toxicity
Authors: Yinghong Wang, Robert R. Jenq, Jennifer A. Wargo, Stephanie S. Watowich
Journal: The Journal of Experimental Medicine (2023)

Immunotherapy has greatly improved cancer outcomes, yet variability in response and off-target tissue damage can occur with these treatments, including immune checkpoint inhibitors (ICIs). Multiple lines of evidence indicate the host microbiome influences ICI response and risk of immune-related adverse events (irAEs). As the microbiome is modifiable, these advances indicate the potential to manipulate microbiome components to increase ICI success. We discuss microbiome features associated with ICI response, with focus on bacterial taxa and potential immune mechanisms involved in irAEs, and the overall goal of driving novel approaches to manipulate the microbiome to improve ICI efficacy while avoiding irAE risk.
Manipulation of IME4 expression, a global regulation strategy for metabolic engineering in Saccharomyces cerevisiae
Authors: Jianxun Zhu, Tianyue An, Wenlong Zha, Ke Gao, Ting Li, Jiachen Zi
Journal: Acta Pharmaceutica Sinica B (2023)

Metabolic engineering has been widely used for production of natural medicinal molecules. However, engineering high-yield platforms is hindered in large part by limited knowledge of complex regulatory machinery of metabolic network. N6-Methyladenosine (m6A) modification of RNA plays critical roles in regulation of gene expression. Herein, we identify 1470 putatively m6A peaks within 1151 genes from the haploid Saccharomyces cerevisiae strain. Among them, the transcript levels of 94 genes falling into the pathways which are frequently optimized for chemical production, are remarkably altered upon overexpression of IME4 (the yeast m6A methyltransferase). In particular, IME4 overexpression elevates the mRNA levels of the methylated genes in the glycolysis, acetyl-CoA synthesis and shikimate/aromatic amino acid synthesis modules. Furthermore, ACS1 and ADH2, two key genes responsible for acetyl-CoA synthesis, are induced by IME4 overexpression in a transcription factor-mediated manner. Finally, we show IME4 overexpression can significantly increase the titers of isoprenoids and aromatic compounds. Manipulation of m6A therefore adds a new layer of metabolic regulatory machinery and may be broadly used in bioproduction of various medicinal molecules of terpenoid and phenol classes.
Community Mental Health Services for American Indians and Alaska Natives: Reconciling Evidence-Based Practice and Alter-Native Psy-ence
Authors: Joseph P. Gone
Journal: Annual Review of Clinical Psychology (2023)

This review updates and extends Gone &amp; Trimble's (2012) prior review of American Indian (AI) and Alaska Native (AN) mental health. First, it defines AI/AN populations in the USA, with an explanation of the importance of political citizenship in semisovereign Tribal Nations as primary for categorizing this population. Second, it presents an updated summary of what is known about AI/AN mental health, with careful notation of recurrent findings concerning community inequities in addiction, trauma, and suicide. Third, this article reviews key literature about AI/AN community mental health services appearing since 2010, including six randomized controlled trials of recognizable mental health treatments. Finally, it reimagines the AI/AN mental health enterprise in response to an “alter-Native psy-ence,” which recasts prevalent mental health conditions as postcolonial pathologies and harnesses postcolonial meaning-making through Indigenized therapeutic interventions. Ultimately, AI/AN Tribal Nations must determine for themselves how to adopt, adapt, integrate, or refuse specific mental health treatments and services for wider community benefit.
Disparities in cancer incidence by rurality in California
Authors: Debora L Oh, Karen Schumacher, Juan Yang, Katarina Wang, Katherine Lin, Scarlett Lin Gomez, Salma Shariff-Marco
Journal: JNCI Journal of the National Cancer Institute (2023)

Cancer rates in rural areas across the United States have different patterns than in urban areas. This study examines associations between rurality and incidence for the top 5 cancers in California and evaluates whether these associations vary jointly by sex, race, and ethnicity.
Outcomes of Omicron sub-lineages BA.1.1 and BA.2 infection compared with the sub-lineage BA.1 infection in emergency departments' patients
Authors: Donia Bouzid, Thomas Kapfer, Stéphane Marot, Vittiaroat Ing, Valentine Marie Ferré, Anthony Chauvin, Jérôme Le Goff, Sami Ellouze, Maud Salmona, Christelle Hermand, Arthur Bourg, Aurélie Schnuriger, Florent Fémy, Méryl Nguyen Van Tinh, Ségolène Brichler, David Veyer, Pierrick Le Borgne, Samira Fafi-Kremer, Anne Sophie L'Honneur, Clément Augustin, Tabassome Simon, Marine Cachanado, Yonathan Freund
Journal: Clinical Microbiology and Infection (2023)
Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
Authors: Iris Nederlof, Leonie Voorwerk, Marleen Kok
Journal: Clinical Cancer Research (2023)

A substantial fraction of early-stage triple-negative breast cancer (eTNBC) is characterized by high levels of stromal tumor-infiltrating lymphocytes (sTIL) and has a good prognosis even without systemic treatment, highlighting the importance of an endogenous anticancer immune response. Still, a considerable proportion of patients with eTNBC need some "therapeutical push" to kick-start this immune response. Exploiting this immune response with immune-checkpoint inhibition (ICI), in combination with chemotherapy, has made its way into standard of care in eTNBC. Major challenges in the near future include finding those patients with eTNBC who can be treated with ICI alone or with a reduced chemotherapy backbone. Exploring the optimal duration of ICI and finding biomarkers to predict response will be key to enable personalized implementation of ICI in patients with eTNBC. For patients who currently do not respond effectively to ICI plus chemotherapy, challenges lie in finding new immunomodulatory therapies and developing response-guided neoadjuvant approaches.
Labeling Assembly of Hydrophilic Methionine into Nanoparticle for Mild‐Heat Mediated Immunometabolic Therapy
Authors: Xiao Zheng, Ying Liu, Tingting Zhang, Yuge Zhao, Yiqiong Liu, Jie Zang, Gaowei Chong, Yan Li, Yushan Yang, Yan Yang, Jingjing Gu, Ruiqing He, Bingbing Liu, Weimin Yin, Haiqing Dong, Yongyong Li
Journal: Advanced Healthcare Materials (2023)

Methionine metabolism has a significant impact on T cells' survival and activation even in comparison to arginine, a well-documented amino acid in metabolic therapy. However, hydrophilic methionine is hardly delivered into TME due to difficult loading and rapid diffusion. Herein, the labeling assembly of methionine into nanoparticle is developed to overcome high hydrophilicity for mild-heat mediated immunometabolic therapy. The strategy is to first label methionine with protocatechualdehyde (as the tag) via reversible Schiff-base bond, and then drive nanoassembly of methionine (MPC@Fe) mediated by iron ions. In this fashion, a loading efficiency of 40% and assembly induced photothermal characteristics can be achieved. MPC@Fe can accumulate persistently in tumor up to 36 h due to tumor-selective aggregation in acidic TME. A mild heat of 43 °C on tumor by light irradiation stimulated the immunogenic cell death and effectively generated CD8+ T cells. Notably, MPC@Fe assisted by mild heat promoted 4.2-fold of tumor-infiltrating INF-γ+ CD8+ T cells, leading to an inhibition ratio of 27.3-fold versus the free methionine. Such labeling assembly provides a promising methionine delivery platform to realize mild heat mediated immunometabolic therapy, and is potentially extensible to other amino acids.
Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Authors: Chiara Falcomatà, Stefanie Bärthel, Günter Schneider, Roland Rad, Marc Schmidt-Supprian, Dieter Saur
Journal: Cancer Discovery (2023)

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive tumor microenvironment (TME) constitutes an important roadblock to their efficacy. The landscape of the TME differs substantially across PDAC subtypes, indicating context-specific principles of immunosuppression. In this review, we discuss how PDAC cells, the local TME, and systemic host and environmental factors drive immunosuppression in context. We argue that unraveling the mechanistic drivers of the context-specific modes of immunosuppression will open new possibilities to target PDAC more efficiently by using multimodal (immuno)therapeutic interventions. Immunosuppression is an almost universal hallmark of pancreatic cancer, although this tumor entity is highly heterogeneous across its different subtypes and phenotypes. Here, we provide evidence that the diverse TME of pancreatic cancer is a central executor of various different context-dependent modes of immunosuppression, and discuss key challenges and novel opportunities to uncover, functionalize, and target the central drivers and functional nodes of immunosuppression for therapeutic exploitation.
Pulse Oximeters and Violation of Federal Antidiscrimination Law
Authors: Annabel Kupke, Carmel Shachar, Christopher Robertson
Journal: JAMA (2023)

This Viewpoint discusses how some pulse oximeters can provide incorrect oxygen saturation data for dark-skinned patients compared with light-skinned patients, describes the reasons that biased oximeters remained in use, and highlights why a rule recently proposed by the US Department of Health and Human Services may bring about needed change in the use of pulse oximetry for patients with dark skin.
Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Authors: Min Wu, Lingxiang Wu, Wei Wu, Mengyan Zhu, Jianyu Li, Ziyu Wang, Jie Li, Rong Ding, Yuan Liang, Liangyu Li, Tingting Zhang, Bin Huang, Yun Cai, Kening Li, Lu Li, Rui Zhang, Baoli Hu, Fan Lin, Xiuxing Wang, Siyuan Zheng, Jian Chen, Yongping You, Tao Jiang, Junxia Zhang, Hongshan Chen, Qianghu Wang
Journal: Cancer Research (2023)

Abstract Tumor-associated macrophages (TAM) play a crucial role in immunosuppression. However, how TAMs are transformed into immunosuppressive phenotypes and influence the tumor microenvironment (TME) is not fully understood. Here, we utilized single-cell RNA sequencing and whole-exome sequencing data of glioblastoma (GBM) tissues and identified a subset of TAMs dually expressing macrophage and tumor signatures, which were termed double-positive TAMs. Double-positive TAMs tended to be bone marrow–derived macrophages (BMDM) and were characterized by immunosuppressive phenotypes. Phagocytosis of glioma cells by BMDMs in vitro generated double-positive TAMs with similar immunosuppressive phenotypes to double-positive TAMs in the GBM TME of patients. The double-positive TAMs were transformed into M2-like macrophages and drove immunosuppression by expressing immune-checkpoint proteins CD276, PD-L1, and PD-L2 and suppressing the proliferation of activated T cells. Together, glioma cell phagocytosis by BMDMs in the TME leads to the formation of double-positive TAMs with enhanced immunosuppressive phenotypes, shedding light on the processes driving TAM-mediated immunosuppression in GBM. Significance: Bone marrow–derived macrophages phagocytose glioblastoma cells to form double-positive cells, dually expressing macrophage and tumor signatures that are transformed into M2-like macrophages and drive immunosuppression.
Errors in Results
Journal: JAMA Neurology (2023)

Andreas Bartley, MD; Jiri Bartek Jr, MD, PhD; Asgeir S. Jakola, MD, PhD; Jimmy Sundblom, MD, PhD; Marie Fält, RN, MSc; Petter Förander, MD, PhD; Niklas Marklund, MD, PhD; Magnus Tisell, MD, PhD
Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children
Authors: Yunha Noh, Han Eol Jeong, Ahhyung Choi, Eun-Young Choi, Björn Pasternak, Hedvig Nordeng, Mette Bliddal, Kenneth K. C. Man, Ian C. K. Wong, Dong Keon Yon, Ju-Young Shin
Journal: JAMA Pediatrics (2023)

Existing observational data have indicated positive associations of acid-suppressive medication (ASM) use in prenatal and early life with allergic diseases in children; however, no study to date has accounted for confounding by indication or within-familial factors.
Does Cytomegalovirus Play a Role in Pediatric Lymphoblastic Leukemogenesis?
Authors: Joseph L. Wiemels
Journal: JAMA Network Open (2023)

Jennifer M. Geris, PhD, MPH; Mark R. Schleiss, MD; Anthony J. Hooten, BS; Erica Langer, BES; Nelmary Hernandez-Alvarado, MS; Michelle A. Roesler, BS; Jeannette Sample, MPH; Lindsay A. Williams, PhD, MPH; David S. Dickens, MD; Rajen J. Mody, MBBS, MS; Yaddanapudi Ravindranath, MD; Kate L. Gowans, MD; Matthew G. Pridgeon, MD; Logan G. Spector, PhD; Heather H. Nelson, PhD, MPH